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Abstract
 
The short life span of granulocytes, which limits many inflammatory responses, is thought to be
influenced by the Bcl-2 protein family, death receptors such as CD95 (Fas/APO-1), stress-acti-
vated protein kinases such as p38 mitogen-activated protein kinase (MAPK), and proinflamma-
tory cytokines like granulocyte colony-stimulating factor (G-CSF). To clarify the roles of these
various regulators in granulocyte survival, we have investigated the spontaneous apoptosis of
granulocytes in culture and that induced by Fas ligand or chemotherapeutic drugs, using cells
from normal, CD95-deficient 
 
lpr
 
, or 
 
vav-bcl-2 
 
transgenic mice. CD95-induced apoptosis,
which required receptor aggregation by recombinant Fas ligand or the membrane-bound
ligand, was unaffected by G-CSF treatment or Bcl-2 overexpression. Conversely, spontaneous
 
and drug-induced apoptosis occurred normally in 
 
lpr 
 
granulocytes but were suppressed by G-CSF
treatment or Bcl-2 overexpression. Although activation of p38 MAPK has been implicated in
granulocyte death, their apoptosis actually was markedly accelerated by specific inhibitors of
this kinase. These results suggest that G-CSF promotes granulocyte survival largely through the
Bcl-2–controlled pathway, whereas CD95 regulates a distinct pathway to apoptosis that is not
required for either their spontaneous or drug-induced death. Moreover, p38 MAPK signaling
contributes to granulocyte survival rather than their apoptosis.
Key words: apoptosis • Bcl-2 • Fas ligand • p38 mitogen-activated protein kinase • 
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Introduction
 
Production of granulocytes from common myeloid precur-
sors in the bone marrow is regulated in part by cytokines
such as G-CSF and GM-CSF (1). After their release into
the blood stream, granulocytes can migrate into tissues
where they act as phagocytes of bacteria. The inflammatory
responses mediated by granulocytes are curtailed by their
short life span, which is determined by an intrinsic suicide
program involving activation of proteases of the caspase
family. The programmed demise of these cells prevents ex-
cessive release of histotoxic substances, and promotes sub-
sequent clearance of the remaining apoptotic bodies by
 
macrophages
 
 
 
(2, 3). The biologic mechanisms that regulate
granulocyte apoptosis are poorly understood, although it is
well known that their survival is promoted by inflamma-
tory cytokines such as G-CSF, GM-CSF, and IL-5, as well
as by microbial substances, like LPS (1, 4). The pathways
controlling their viability have been variously suggested to
involve the Bcl-2 family of intracellular proteins (5–7),
death receptors (8–10), and stress-activated protein kinases
(11, 12).
The Bcl-2 family of proteins has been shown to regulate
granulocyte survival. Although Bcl-2 and Bcl-X
 
L
 
 are ex-
pressed at very low or undetectable levels in granulocytes
(5, 13, 14), these cells do express the related antiapoptotic
family members Mcl-1 and A1 (5–7). Moreover, levels of
Mcl-1 and A1 are upregulated by proinflammatory cyto-
kines or LPS, and Mcl-1 levels in myeloid progenitor cells
decline upon growth factor withdrawal (5, 15). In addition,
granulocytes from mice lacking one of the genes for A1
undergo accelerated apoptosis when cultured in simple me-
dium, but exhibit normal sensitivity to TNF (16).
Granulocytes bear CD95 (Fas/APO-1) and TNF-R1 on
their surfaces, and the Ab- or ligand-mediated activation of
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these receptors triggers their apoptotic death (8–10). The
observation that antagonistic Abs to CD95 (Fas/APO-1)
delayed spontaneous apoptosis of human granulocytes in
culture led to the suggestion that the Fas ligand (FasL)/
CD95 system modulates their life span (9, 17, 18). This no-
tion, however, has been challenged by reports which dem-
onstrated that spontaneous granulocyte death, granulocyte
cellularity, and the colony-forming potential of myeloid
precursors are all normal in CD95-deficient lymphoprolif-
eration (
 
lpr
 
1
 
 
 
[19]) and FasL mutant generalized lymphade-
nopathy (
 
gld
 
) mice (20).
The stress-activated kinase p38 mitogen-activated pro-
tein kinase (MAPK), a serine/threonine kinase whose tar-
gets include the activating transcription factor 2 (ATF-2)
and myocyte enhancer factor 2 (MEF-2) transcription fac-
tors (21), is activated in dying granulocytes (11, 12). Inhibi-
tion of p38 MAPK activity using synthetic inhibitors was
reported to delay neutrophil apoptosis in culture, whereas
blocking the related extracellular signal–regulated kinase
(ERK) pathway had no effect (11, 12). This observation led
to the assumption that activation of p38 MAPK is a prereq-
uisite for granulocyte apoptosis.
To explore how these different signaling pathways inter-
act in regulating the life span of granulocytes, we have ana-
lyzed the survival of resting and peritoneal exudate granu-
locytes derived from wild-type (
 
wt
 
), CD95-deficient 
 
lpr
 
mutant, and 
 
vav-bcl-2
 
 transgenic mice, both during culture
in simple medium and after treatment with FasL or chemo-
therapeutic drugs. We have also investigated how signals
from G-CSF and p38 MAPK impact granulocyte apoptosis.
Our results demonstrate that multimerization of CD95
(Fas/APO-1) is required to induce cell death in granulo-
cytes. We observed that activation of granulocytes with
G-CSF or overexpression of Bcl-2 delayed spontaneous and
drug-induced apoptosis but not FasL-mediated death,
whereas only the latter was prevented by the absence of
CD95 (Fas/APO-1). FasL and Bcl-2, therefore, regulate
distinct apoptotic pathways in granulocytes. We further
demonstrate that signaling through p38 MAPK, rather than
promoting apoptosis in granulocytes, as previously re-
ported, is required to maintain their survival.
 
Materials and Methods
 
Mice.
 
The generation of the
 
 vav-bcl-2
 
-68 and
 
 
 
-69 transgenic
mouse strains expressing a human 
 
bcl-2
 
 cDNA under control of
the 
 
vav
 
 promoter at high levels in all hematopoetic cell types has
been described (22). All C57BL/6 and C57BL/6 
 
lpr
 
 mice were
bred in The Walter and Eliza Hall Institute Animal Facility in
Kew (Victoria) and were used between 6 and 12 wk of age.
 
Cell Culture and Reagents.
 
Neuro2A neuroblastoma cells
stably expressing membrane-bound mouse FasL, and control
Neuro2A cells expressing the neomycin resistance gene have
 
been described (23). Resting granulocytes were isolated from the
bone marrow, and peritoneal exudate granulocytes were col-
lected by lavage of the peritoneal cavity of mice that had been in-
jected intraperitoneally 3 h earlier with 2 ml of a 0.5% casein/
PBS solution. Granulocytes and Neuro2A cells were cultured in
the high glucose version of DMEM supplemented with 13 
 
m
 
M
folic acid, 250 
 
m
 
M 
 
l
 
-asparagine, 50 
 
m
 
M 2-ME, and 10% FCS
(TRACE). Human G-CSF (Granocyte™) was provided by AM-
RAD. The pan-caspase inhibitor zVADfmk, the p38 MAPK
inhibitors SB203850 and SB202190, and the MAPK kinase
(MEK)-1 inhibitor PD98059 were purchased from Calbiochem.
Production of recombinant FLAG-tagged FasL has been de-
scribed (24). Etoposide, doxorubicin, and cis-platin were ob-
tained from David Bull Laboratories and DellaWest.
 
Determination of MAPK Activation and Immunoblotting.
 
Cells
(10
 
6
 
) were resuspended in 50 
 
m
 
l lysis buffer (50 mM Tris, 150
mM NaCl, 2 mM EDTA, 1 mM EGTA, pH 7.5, supplemented
with 1 mM Na
 
3
 
VO
 
4
 
, 1 mM NaF, 25 
 
m
 
g/ml aprotinin, leupeptin,
pepstatin, and Pefabloc, and 1% Triton X-100; Sigma-Aldrich).
Samples were cleared by centrifugation (16,000 
 
g
 
, 5 min, 4
 
8
 
C).
Proteins were size-fractionated on SDS-PAGE 4–20% gradient
gels under reducing conditions (Novex) and transferred onto
polyvinyl-difluoridon membranes (Millipore) by electroblotting.
The membranes were incubated for 
 
.
 
12 h at 4
 
8
 
C in blocking
buffer (PBS containing 0.05% Tween-20 and 5% skim milk).
The anti–phospho-p38 MAPK, p38 MAPK, phospho–c-Jun
NH
 
2
 
-terminal kinase (JNK), phospho-ERK, and ERK kinase
Abs (New England Biolabs, Inc.), were diluted at 1:1,000 in
blocking buffer for immunolabeling. The mAbs to mouse Bcl-2
(BD PharMingen), Bcl-X
 
L 
 
(a gift from C. Thompson, University
of Pennsylvania, Philadelphia, PA), Bax (BD PharMingen), Bcl-w
(16H12) (25), or Bim (26) were diluted and used at 2–5 
 
m
 
g/ml in
blocking buffer. Peroxidase-conjugated rabbit anti–mouse Ig Abs
(Silenus) or goat anti–rat Ig Abs (Southern Biotechnology Associ-
ates, Inc.) served as secondary reagents (1:1,000), and the en-
hanced chemiluminescence system was used for detection. To
demonstrate equal protein loading of the gel, membranes were
reprobed with polyclonal goat antiserum sc-535-G specific for
p38 MAPK (Santa Cruz Biotechnology, Inc.), an antiserum spe-
cific for ERK1 and ERK2 (New England Biolabs, Inc.), or a
mouse mAb to heat shock protein (Hsp)70 (a gift from R.
Anderson, Peter MacCallum Cancer Institute, Melbourne, Aus-
tralia).
 
Cell Sorting and Immunofluorescence Analysis.
 
Granulocytes
were stained with FITC-labeled rat anti–Gr-1 mAb RB6-8C5 (5
 
m
 
g/ml) in PBS/10% FCS, 30 min on ice) and sorted on a MoF-
low sorter (Cytomation) after gating on the basis of the forward
and side light scatter and exclusion of dead cells using propidium
iodide staining. Sorted granulocytes from the bone marrow and
the peritoneal cavity were
 
 
 
.
 
98% positive for Gr-1 and Mac-1,
but negative for the B cell marker B220, the T cell marker Thy-1,
the erythroid cell marker TER-119, and the macrophage marker
F4/80.
Expression of transgenic human Bcl-2 protein was assessed in
granulocytes sorted by staining bone marrow cells with Abs to
Thy1, B220, Ter119, and F4/80 to exclude nongranulocytic cells
from analysis, followed by cytoplasmic immunofluorescence
staining (27). Cells (0.2 
 
3
 
 10
 
6
 
) were fixed for 10 min at room
temperature in 1 ml 1% paraformaldehyde in PBS. After washing
twice with PBS, cells were resuspended in FACS
 
®
 
 buffer (bal-
anced salt solution, 2% FCS, 10 mM sodium azide) containing
0.3% saponin (Sigma-Aldrich) and 2 
 
m
 
g/ml mouse anti–human
Bcl-2 mAb, Bcl-2-100 (a gift from D. Mason, University of Ox-
 
1
 
Abbreviations used in this paper:
 
 ERK, extracellular signal regulating kinase;
FADD, Fas-associated death domain; GST, glutathione 
 
S
 
-transferase;
Hsp, heat shock protein; JNK, c-jun NH
 
2
 
-terminal kinase; 
 
lpr
 
, lympho-
proliferation; MAPK, mitogen-activated protein kinase; MEK, MAPK
kinase; NF, nuclear factor; 
 
wt
 
, wild-type. 
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ford, Oxford, UK). After 30 min on ice, cells were washed in
FACS
 
®
 
 buffer containing 0.03% saponin and incubated with
FITC-labeled goat anti–mouse IgG–specific Ab (5 
 
m
 
g/ml in
FACS
 
®
 
 buffer containing 0.3% saponin) for 30 min on ice. After
a final wash, the cells were resuspended in 200 
 
m
 
l FACS
 
®
 
 buffer
and 5,000 cells per sample were analyzed on a FACScan™ (Bec-
ton Dickinson). Cells from C57BL/6 mice stained with Bcl-2-
100 mAb served as a negative control for transgene expression.
Expression of mouse Bcl-2, Bcl-X
 
L
 
, and Bax proteins was as-
sessed in granulocytes sorted by staining bone marrow cells with
Abs to Thy1, B220, Ter119, and F4/80 to exclude nongranulo-
cytic cells from analysis, followed by cytoplasmic immunofluores-
cence staining (27) using the following mAbs: hamster anti–mouse
Bcl-2 (BD PharMingen), mouse anti-Bax (BD PharMingen), or
mouse anti–Bcl-X
 
L
 
 Abs. FITC-labeled goat anti–mouse IgG Abs
or goat anti–hamster IgG Abs (BD PharMingen) were used as
secondary reagents at 1:100 dilution in FACS
 
®
 
 buffer containing
0.3% saponin. Expression of CD95 (Fas/APO-1) and FasL on na-
ive granulocytes or Neuro2A cells was determined by surface im-
munofluorescence staining using mAbs specific to mouse CD95
(Fas/APO-1) (JO-2; BD PharMingen) and FasL (Kay-10; BD
PharMingen). FITC-labeled goat anti–mouse IgG Abs or goat
anti–hamster IgG Abs (Silenus) were used as secondary reagent.
Samples stained with secondary reagent alone served as a negative
control.
 
Cell Death Assays.
 
The percentage of viable cells in culture
was determined by staining with 2 
 
m
 
g/ml propidium iodide and
analyzing the samples on a FACScan™ (Becton Dickinson). Al-
ternatively, cells were stained with trypan blue (0.1% in PBS) and
analyzed in a hemocytometer. As cell death–inducing stimuli we
used coculture with FasL-expressing Neuro2A cells or control
Neuro2A cells, 1–1,000 ng/ml FLAG-tagged recombinant hu-
man FasL (24), 10–50 
 
m
 
g/ml etoposide, 50 
 
m
 
g/ml cis-platin, or
500 ng/ml doxorubicin. Recombinant FasL was aggregated by
the addition of 0.5 
 
m
 
g/ml M2 anti-FLAG mAb (Sigma-Aldrich).
 
Statistical Analysis.
 
Degrees of significance for the comparison
of effects of FasL, G-CSF, drug treatment, or Bcl-2 overexpres-
sion on survival of granulocytes were assessed using the Student’s
paired 
 
t
 
 test and a Microsoft Excel software program. 
 
P
 
 
 
, 
 
0.04
was considered to indicate statistically significant differences.
 
Results
 
Receptor Multimerization Is Needed for FasL-induced Apop-
tosis.
 
It has been shown that CD95-induced apoptosis in
lymphocytes requires receptor multimerization either by
the physiological membrane-bound FasL or by aggregated
recombinant FasL. In contrast, soluble FasL did not kill
cells, and at high concentrations could even act as an antag-
onist of membrane-bound FasL (23, 24, 28, 29). To assess
whether these observations apply only to lymphocytes or
are of general importance, we compared the death-induc-
ing potency of soluble or aggregated FasL on granulocytes
from bone marrow of 
 
wt 
 
and CD95-deficient mutant 
 
lpr
 
mice. Immunofluorescence staining and flow cytometric
analysis revealed that CD95 is expressed on granulocytes
from 
 
wt 
 
mice (Fig. 1 a) but, as expected, not on those from
 
lpr
 
 mice
 
 
 
(30; Fig. 1 b). Only multimerized or membrane-
bound FasL could induce significant killing of 
 
wt
 
 granulo-
cytes (Fig. 1 c). This effect was exclusively mediated via
CD95, since cells from 
 
lpr 
 
mice were completely resistant
 
to such treatment (Fig. 1 c).
 
 
 
To exclude a nonspecific toxic
effect of the M2 anti-FLAG mAb or the FasL–anti-FLAG
mAb immune complex on granulocytes, we showed that
neither the M2 anti-FLAG mAb alone nor immune com-
plexes of FLAG–Fas-associated death domain(FADD)–glu-
tathione 
 
S
 
-transferase (GST) fusion proteins plus M2 anti-
FLAG mAb killed granulocytes (Fig. 1 c).
These results demonstrate that FasL-induced apoptosis in
granulocytes requires receptor multimerization and not
simply trimerization.
 
CD95 and Bcl-2 Regulate Distinct Pathways to Apoptosis in
Granulocytes.
 
It has been controversial whether members
of the Bcl-2 family can regulate CD95-induced apoptosis.
Although some reports have indicated that CD95-induced
apoptosis in lymphocytes or hepatocytes could be regulated
by Bcl-2 and related proteins (31–33), we and others have
shown that CD95 and the Bcl-2 family regulate two dis-
tinct pathways to cell death (27, 34–38). To determine
whether Bcl-2 can modulate FasL-induced death in granu-
locytes, we exploited 
 
vav-bcl-2
 
 transgenic mice, which ex-
press a human 
 
bcl-2
 
 cDNA under control of the 
 
vav
 
 pro-
moter in all hematopoietic cell types (22). Expression of the
transgene-encoded human Bcl-2 protein in granulocytes
was confirmed by immunofluorescence staining and flow
cytometric analysis (Fig. 2, a and b). The effect of Bcl-2 on
FasL-induced apoptosis was analyzed by comparing survival
of granulocytes from 
 
wt
 
, CD95-deficient 
 
lpr
 
, and 
 
vav
 
-
 
bcl-2
 
transgenic mice. Multimerized FasL killed 
 
wt
 
 granulocytes
in a dose- and time-dependent manner (Fig. 2, c and h).
Figure 1. Receptor multimer-
ization is required for FasL-
induced killing of granulocytes.
CD95 expression was deter-
mined on sorted bone marrow–
derived granulocytes from (a) wt
and (b) lpr mice by indirect im-
munofluorescence staining and
flow cytometric analysis. Control
staining is shown by filled histo-
grams. Specific staining for
CD95 is shown by open histo-
grams. (c) Sorted granulocytes
from bone marrow of wt or lpr
mice were cultured for 24 h in
the absence or presence of 100
ng/ml soluble FasL or multimer-
ized FasL or with Neuro2A cells
expressing membrane-bound
FasL. Treatment with M2 anti-
FLAG mAb (500 ng/ml) with or
without a FLAG–FADD-GST
fusion protein (1 mg/ml) served
as additional controls. Viability
was assessed by trypan blue stain-
ing and analysis in a hemocy-
tometer. Data shown represent
arithmetic means 6 SD of three
independent experiments and
animals. A statistically significant
degree of cell killing was only
observed in wt cells treated with either multimerized (P , 0.0003) or
membrane-bound FasL (P , 0.009). 
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Notably, no difference was observed between 
 
wt
 
 and 
 
bcl-2
 
transgenic cells (Fig. 2, c, d, and h) but, as expected, CD95-
deficient 
 
lpr
 
 cells were completely resistant to FasL (Fig. 2, e
and h). The cytotoxicity observed after treatment of granu-
 
locytes from 
 
wt
 
 and 
 
vav-bcl-2 transgenic mice with high
concentrations of soluble FasL indicates that some aggrega-
tion of CD95 occurs in the absence of cross-linking Ab.
It is conceivable that recombinant FasL multimerized by
an anti-FLAG Ab does not perfectly mimic the physiologi-
cal membrane-bound FasL. Therefore, we cocultured
granulocytes with the CD95-negative neuroblastoma cell
line Neuro2A, engineered to express membrane-bound
FasL (24). Like the multimerized recombinant FasL, mem-
brane-bound FasL induced apoptosis in granulocytes from
wt and vav-bcl-2 but not in those from lpr mice (Fig. 2 f).
Coculture with control Neuro2A cells transfected with a
neo construct did not significantly affect granulocyte sur-
vival (Fig. 2 f). A time course experiment confirmed the
equal sensitivity of wt and bcl-2 transgenic granulocytes to
FasL-induced killing, whereas lpr granulocytes were resis-
tant to this treatment (Fig. 2, e and h)
To prove that the transgenic Bcl-2 protein was func-
tional, we cultured granulocytes from vav-bcl-2 mice in the
absence of supportive cytokines, or treated them with the
chemotherapeutic anticancer drugs etoposide, cis-platin, or
doxorubicin. In contrast to FasL-induced apoptosis, the
spontaneous cell death, as well as drug-induced death, was
significantly inhibited by overexpression of Bcl-2 (Fig. 2 g
and Fig. 3, a and b).
The FasL/CD95 system has been implicated in the spon-
taneous death of granulocytes (9) and in drug-induced cell
killing (39). Therefore, we assessed the contribution of the
FasL/CD95 system to spontaneous and drug-induced kill-
ing of granulocytes by comparing survival of cells from wt
and CD95-deficient lpr mice. The granulocytes were either
treated with etoposide, cis-platin, or doxorubicin for up to
72 h or were left untreated. We detected no differences in
spontaneous death rates or drug-induced killing between
granulocytes from wt and lpr mice (Fig. 2 g and Fig. 3, a
and c).
We also investigated whether the tissue localization (and
perhaps activation status) influences the sensitivity of gran-
ulocytes to spontaneous death in culture or to treatment
with FasL or antitumor drugs. Therefore, mice were in-
jected intraperitoneally with casein and granulocytes were
sorted from peritoneal exudate cells. We observed that
spontaneous death of peritoneal exudate granulocytes in
culture was accelerated compared with resting granulocytes
from the bone marrow (Fig. 3, a and d). Peritoneal exudate
granulocytes were sensitive to FasL, and Bcl-2 provided no
protection (Fig. 3, d and e), although it significantly de-
layed spontaneous and etoposide-induced apoptosis in
these cells (Fig. 3, d and e). On the other hand, the spon-
taneous and drug-induced death of peritoneal exudate
lpr granulocytes was not affected by the absence of CD95
(Fig. 3 f).
Collectively, these results demonstrate that CD95 and
Bcl-2 regulate distinct pathways to apoptosis in granulo-
cytes, and that the FasL/CD95 system is not required for
their spontaneous or drug-induced death. Conversely, Bcl-2
is a potent inhibitor of these pathways to cell death but has
no impact on FasL-induced killing.
Figure 2. Bcl-2 and FasL regulate distinct pathways to apoptosis in
granulocytes. Expression of transgene-encoded human Bcl-2 was deter-
mined on sorted bone marrow–derived granulocytes from (a) wt and (b)
vav-bcl-2 transgenic mice by indirect immunofluorescence staining and
flow cytometric analysis. The Bcl-2-100 Ab used recognizes specifically
human but not mouse Bcl-2. Control staining is shown by filled histo-
grams and specific staining for human Bcl-2 by open histograms. Granu-
locytes from bone marrow of (c) wt, (d) vav-bcl-2 transgenic, or (e) lpr
mice were sorted and treated with graded concentrations of soluble FasL
or FasL multimerized with M2 anti-FLAG mAb. Alternatively, granulo-
cytes were cocultured with (f) control (neo) or FasL-expressing Neuro2A
cells. Cell viability was determined after 24 h. In a kinetic analysis, sorted
granulocytes were cultured in the (g) absence or (h) presence of 100 ng/
ml multimerized FasL for 24, 48, or 72 h. Cell viability was assessed by
propidium iodide staining and flow cytometric analysis. Data shown rep-
resent arithmetic means 6 SD of four independent experiments and ani-
mals. There are no statistically significant differences between FasL-
treated  wt and bcl-2 transgenic cells regardless of time of treatment or the
FasL concentration applied. Survival of granulocytes from vav-bcl-2 trans-
genic mice in simple culture medium was significantly better compared
with that of granulocytes from wt or lpr mice (P , 0.006).651 Villunger et al.
G-CSF Inhibits Spontaneous and Drug-induced Granulocyte
Apoptosis but Has No Influence on FasL-induced Cell Death.
Cytokines can influence the expression levels and activity
of pro as well as antiapoptotic members of the Bcl-2 family
(5–7). Therefore, we investigated the effects of G-CSF on
granulocyte survival in culture. Pretreatment of bone mar-
row–derived granulocytes with G-CSF delayed spontane-
ous cell death (Fig. 4 a), as well as apoptosis induced by the
anticancer drugs etoposide (Fig. 4 b) and doxorubicin (Fig.
4 c), but had no effect on cis-platin– or FasL-induced cell
death (Fig. 4, d and e). Similarly, G-CSF pretreatment of
peritoneal exudate granulocytes significantly delayed
spontaneous apoptosis (Fig. 4 f), but did not impair FasL-
induced killing (Fig 4 g). Although G-CSF protected bone
marrow granulocytes against etoposide-induced apoptosis,
it provided almost no protection to peritoneal exudate
granulocytes, perhaps due to their rapid kinetics of sponta-
neous death under these conditions (Fig. 4 h).
Since treatment with G-CSF increases the expression of
the antiapoptotic Bcl-2 family members A1 and Mcl-1 in
myeloid cells (5, 15), we investigated whether G-CSF can
also regulate other Bcl-2 family members. Granulocytes
from bone marrow were cultured for 0, 4, or 16 h in the
presence or absence of G-CSF. Expression of Bcl-2, Bcl-
XL, and Bax within the Gr-11 population was determined
by cytoplasmic immunofluorescence staining of fixed, per-
meabilized cells and flow cytometric analysis. Freshly iso-
lated granulocytes expressed low level of Bcl-2, Bcl-XL,
and Bax, and G-CSF did not notably alter their expression
levels (data not shown). As in lymphoid cells (26), levels of
Bim were below the threshold of detection by immunoflu-
Figure 3. Bcl-2 inhibits spontaneous and drug-induced apoptosis in
bone marrow and peritoneal exudate granulocytes. (a–c) Granulocytes
from bone marrow or (d–f) peritoneal exudate of casein-injected (a and d)
wt, (b and e) vav-bcl-2 transgenic, or (c and f) lpr mice were sorted and cul-
tured with the anticancer drugs etoposide (10 mg/ml), cis-platin (50 mg/
ml), doxorubicin (0.5 mg/ml), multimerized FasL (100 ng/ml), or were
left untreated. Cell viability was determined at the indicated times as de-
scribed in the legend to Fig. 2. Data shown represent arithmetic means 6
SD of four independent experiments and four to seven animals. There
was no statistically significant difference between FasL-treated wt or bcl-2
transgenic granulocytes, regardless of time point analyzed and origin of
the cells (P . 0.05 or higher). Granulocytes from vav-bcl-2 transgenic
mice died at significantly slower rates when cultured in simple medium or
after drug treatment than granulocytes derived from wt or lpr mice, again
regardless of their activation status (P , 0.03 or lower). No significant
difference was observed between wt- and lpr-derived granulocytes after
drug treatment (P . 0.13 or higher).
Figure 4. G-CSF inhibits spontaneous and drug-induced apoptosis of
granulocytes. (a–e) Granulocytes were isolated from bone marrow (f–h)
or peritoneal cavity of wt mice that had been injected with casein. Cells
were cultured in the absence (open circles) or presence of 100 ng/ml hu-
man G-CSF (filled circles), which was added 30 min before the addition
of death stimuli. Cells were cultured in (a and f) medium alone or (b and
h) in the presence of 10 mg/ml etoposide, (c) 50 mg/ml cis-platin, (d) 0.5
mg/ml doxorubicin, or (e and g) 100 ng/ml cross-linked FasL. Cell via-
bility was assessed as in the legend to Fig. 2. Data shown represent arith-
metic means 6 SD of three to four independent experiments and animals.
G-CSF treatment significantly inhibited spontaneous and drug-induced
apoptosis of resting wt granulocytes after treatment with etoposide or
doxorubicin (P , 0.035 or lower) but had no statistically significant im-
pact on cell death induced by cis-platin or FasL. In granulocytes from
peritoneal exudate only spontaneous death was significantly delayed by
G-CSF treatment (P , 0.004).652 Regulators of Granulocyte Apoptosis
orescence staining (data not shown). Immunoblotting con-
firmed the results obtained by flow cytometric analysis and
also revealed that granulocytes express low levels of the an-
tiapoptotic protein Bcl-w (Fig. 5).
Collectively, these results show that G-CSF can inhibit
spontaneous and chemotherapeutic drug–induced apoptosis
but has no effect on FasL-mediated cell killing. Although
G-CSF may well mediate survival by inducing expression
of Bcl-2 family members such as A1 or Mcl-1 (5, 15), it
does not noticeably affect the levels of Bcl-2, Bcl-XL, Bax,
Bcl-w, or Bim in mouse granulocytes.
The Stress-activated Kinase p38 MAPK Promotes Granulocyte
Survival. Stress-activated kinases such as p38 MAPK or
JNK have been implicated in the control of apoptosis (21,
40–42). It has been reported that p38 MAPK is constitu-
tively activated in granulocytes and that this promotes the
death induced by cytokine withdrawal, since synthetic in-
hibitors of p38 MAPK delayed spontaneous but not anti-
CD95 Ab–induced cell death (11, 12). We first investigated
which apoptotic stimuli could activate p38 MAPK or the
related kinase JNK. Sorted granulocytes from wt and lpr
mice were cultured without supporting cytokines, with sol-
uble FasL, multimerized FasL, or etoposide. Analysis of the
cell extracts using an Ab recognizing the phosphorylated
form of p38 MAPK confirmed its constitutive activation in
granulocytes (Fig. 6 a). p38 MAPK activity was augmented
in wt cells treated with multimerized but not soluble FasL.
As expected, no such effect was observed in cells derived
from CD95-deficient lpr mice (Fig. 6 b), but both wt and lpr
granulocytes responded to etoposide with enhanced p38
MAPK activity (Fig. 6, a and b). The membranes were also
probed with Abs specific for activated forms of JNK1 and
JNK2, or the related MAPKs ERK1 and ERK2. No basal
activation of JNK could be detected and application of
multimerized FasL failed to induce phosphorylation of JNK
or ERK. In contrast, phosphorylated JNK and ERK were
readily detected in lysates from spleen cells treated with ani-
somycin or PMA plus ionomycin (data not shown).
To investigate the significance of p38 MAPK activity in
granulocyte apoptosis, we tested whether the specific syn-
thetic inhibitors of p38 MAPK, SB203850 or SB202130,
could modulate spontaneous or FasL-induced cell death.
These inhibitors have been shown to specifically inhibit
p38 MAPK a and b isoforms but not other related kinases
such as p38 MAPK d or g, JNKs, or ERKs (43). We first
analyzed their effect on spontaneous death of granulocytes
after 24 h (Fig. 7 a) and 48 h (not shown) in culture using
as controls cells treated with the solvent DMSO or the
MEK-1 inhibitor PD98059. Contrary to previous reports
(11, 12), the two p38 MAPK inhibitors did not delay but
drastically accelerated spontaneous death of granulocytes in
culture. Whereas these inhibitors enhanced granulocyte
killing in a dose- and time-dependent manner, preincuba-
tion of cells with G-CSF abolished this effect. DMSO or
PD98059, which specifically targets the ERK pathway, had
no significant effect on granulocyte survival (Fig 7 a, and
data not shown).
To investigate whether G-CSF exerts its antiapoptotic
effect by activating the p38 MAPK pathway, we analyzed
lysates from sorted granulocytes treated with G-CSF in
vitro for p38 MAPK activity. Immunoblotting demon-
strated that G-CSF did not augment the basal p38 MAPK
activity but, as reported previously, for human granulocytes
(44) it did significantly elevate ERK phosphorylation (Fig.
7 b). Furthermore, a time course experiment demonstrated
that G-CSF could prevent p38 MAPK inhibitor–induced
apoptosis, whether applied 30 min before, simultaneously,
or even 30 min after addition of SB203580 (Fig. 7 c) or
SB202190 (data not shown).
Collectively, these data indicate that G-CSF inhibits p38
MAPK inhibitor–induced granulocyte killing by activating
Figure 5. Expression of Bcl-2 family mem-
bers in granulocytes. Immunoblot analysis of
Bcl-2, Bcl-w, Bcl-XL, and Bax expression in
extracts from freshly isolated granulocytes (0 h)
or granulocytes after culture for 16 h in me-
dium alone or medium supplemented with 100
ng/ml G-CSF. Filters had to be exposed be-
tween 10 min (Bax, Bcl-XL, and Bcl-w) and 60
min (Bcl-2) to detect signals specific for these
Bcl-2 family members. Membranes were
stripped and re-probed with an anti-Hsp70 Ab
as a loading control.
Figure 6. Multimerized FasL enhances p38 MAPK activity in granulo-
cytes. Sorted granulocytes from bone marrow of (a) wt and (b) lpr mice
were treated with soluble or multimerized FasL (100 ng/ml), with etopo-
side (50 mg/ml), or were left untreated. (b) Spleen cells from wt mice
stimulated with 10 mg/ml anisomycin or 100 ng/ml PMA plus 1 mg/ml
ionomycin served as a positive control for p38 MAPK activation. p38
MAPK activity was determined by immunoblotting of cell extracts using
an Ab specific for phosphorylated p38 MAPK. Equal protein loading was
confirmed by reprobing membranes with an Ab recognizing p38 MAPK
irrespective of its status of phosphorylation.653 Villunger et al.
a survival pathway that can substitute for p38 MAPK sig-
naling. The activation of the ERK pathway by G-CSF
does not seem to be essential for mediating its antiapoptotic
effect, since application of the MEK-1 inhibitor PD98059
did not block G-CSF–induced inhibition of spontaneous
granulocyte death (Fig. 7 a, and data not shown).
The death of granulocytes induced by the p38 MAPK
inhibitors occurred by apoptosis. Dying cells displayed clas-
sical apoptotic morphology, including condensed chroma-
tin and phosphatidylserine exposure (not shown), and cell
killing could be inhibited by overexpression of Bcl-2 (Fig.
8 a) or the broad spectrum caspase inhibitor zVADfmk (Fig.
8 b). The p38 MAPK inhibitor–mediated killing was inde-
pendent of the FasL/CD95 system since lpr granulocytes
were as sensitive as wt cells to these inhibitors (Fig. 8 a).
Discussion
Granulocytes are short-lived in vivo and readily undergo
spontaneous as well as damage-induced apoptosis in cul-
ture. To clarify the control of their death, we have exam-
ined the role of the pathways involving FasL/CD95, G-CSF,
p38 MAPK, and the Bcl-2 protein family.
Experiments with lymphocytes have shown that Abs to
CD95 do not reliably mimic the physiological ligand for
CD95 and that high concentrations of soluble trimeric FasL
can even antagonize the proapoptotic activity of mem-
brane-bound FasL, presumably by restricting the extent of
CD95 aggregation (23, 24, 28). To investigate whether
these findings are also relevant to a different cell type, we
compared the death-inducing properties of soluble, multi-
merized, and membrane-bound FasL on granulocytes (Fig.
1 c). In accordance with the studies on lymphocytes (23,
24, 28), killing by FasL required multimerization of the re-
ceptor, a state not achievable by application of soluble FasL.
Our findings may indicate that FasL-induced apoptosis in
all cell types requires receptor aggregation and not simply
trimerization. Soluble FasL has been reported to trigger
chemotaxis in granulocytes (45, 46). Hence, trimerization
Figure 7. Inhibition of p38 MAPK accelerates death of granulocytes.
(a) Sorted granulocytes from bone marrow of wt mice were cultured in
the absence or presence of human G-CSF (100 ng/ml), which was added
30 min before treatment with either DMSO (0.25%), the p38 MAPK in-
hibitors SB203580 or SB202190, or the MEK-1 inhibitor PD98059. Cell
viability was assessed after 24 h in culture. Both p38 MAPK inhibitors sig-
nificantly accelerated spontaneous apoptosis of resting wt granulocytes (P ,
0.002 or lower). (b) Sorted granulocytes from bone marrow of wt mice
were treated with G-CSF (100 ng/ml) for the time points indicated or
were left untreated. p38 MAPK or ERK1 and ERK2 activity was deter-
mined by immunoblotting of cell extracts using an Ab specific for phos-
phorylated p38 MAPK or phosphorylated ERK1 and ERK2, respectively.
Equal protein loading was confirmed by reprobing membranes with an
Ab recognizing p38 MAPK or ERK1 and ERK2 irrespective of their sta-
tus of phosphorylation. (c) Sorted granulocytes from bone marrow of wt
mice were cultured in the absence or presence of human G-CSF (100 ng/
ml), which was added 30 min before, simultaneously with, or 30 min after
application of the p38 MAPK inhibitor SB203580 (SB). Cell viability was
assessed after 48 h in culture. Data shown represent arithmetic means 6
SD of three to five animals and two independent experiments.
Figure 8. Cell death induced by inhibition of p38 MAPK is mediated
by a Bcl-2–inhibitable and caspase-dependent apoptotic pathway. (a)
Sorted granulocytes from bone marrow of wt, lpr, or vav-bcl-2 transgenic
mice were cultured with either DMSO (0.25%) or the p38 MAPK inhib-
itors SB203580 or SB202190. Cell viability was assessed after 24 h in cul-
ture. (b) Sorted granulocytes from wt mice were cultured in the absence
or presence of the caspase inhibitor zVADfmk (50 mM), which was added
30 min before treatment with either DMSO (0.25%) or the p38 MAPK
inhibitor SB203580. Cell viability was assessed after 24 h in culture as de-
scribed in the legend to Fig. 2. Data shown represent arithmetic means 6
SD of two to four animals.654 Regulators of Granulocyte Apoptosis
or multimerization of CD95 may elicit qualitatively differ-
ent responses in certain cell types.
It is controversial whether CD95-mediated killing can
be inhibited by antiapoptotic members of the Bcl-2 family
(27, 31–33, 36). In addition, the proapoptotic Bcl-2 family
member Bid was reported to connect CD95 signaling with
the Bcl-2 family. This pathway appears to be dispensable
for CD95 killing of lymphocytes but may have a more sig-
nificant role in other cell types, such as hepatocytes (47).
We analyzed whether Bcl-2 overexpression affected FasL-
induced apoptosis by comparing wt, mutant lpr, and vav-bcl-2
transgenic granulocytes. The apoptosis induced by either
multimerized recombinant FasL or membrane-bound FasL
was unaffected by Bcl-2 overexpression (Fig. 2, d, f, and h).
These findings are consistent with observations on thy-
mocytes, resting T cells, and activated T and B cells, in all
of which bcl-2 transgene expression also failed to protect
against CD95-induced apoptosis (23, 27, 35, 48). In addi-
tion, evidence was provided recently that hepatocytes ex-
pressing a bcl-2 transgene retain normal sensitivity to the
cytotoxic effects of multimerized FasL (23). Others have
reported that killing of hepatocytes induced  in vivo by
anti-CD95 Abs can be inhibited by Bcl-2 (32, 33). How-
ever, it is unclear whether anti-CD95 Abs kill hepatocytes
directly or by an indirect mechanism that also involves
IFN-g, as is the case when mice are injected with soluble
FasL and Propionibacterium acnes (49). Collectively, these re-
sults indicate that Bcl-2 does not interfere with FasL-induced
apoptosis in diverse cell types.
In contrast to FasL-induced cell killing, both spontane-
ous and drug-induced apoptosis were significantly reduced
in granulocytes from vav-bcl-2 transgenic mice (Fig. 3, a, b,
d, and e). The protective effect of Bcl-2 on spontaneous
apoptosis of granulocytes was previously demonstrated in
MRP-8-bcl-2 transgenic mice, but its impact on FasL- or
drug-induced cell death was not addressed in that study
(50). Our evidence that Bcl-2 can inhibit the apoptosis in-
duced by etoposide, cis-platin, or doxorubicin is consistent
with the observation that Bcl-2 protects bone marrow cells
against drug-induced myelosuppression (51). However, a
caveat for attempts to use overexpression of Bcl-2 to rescue
bone marrow cells from chemotherapy-induced cytotoxic-
ity is that the Bcl-2–based protection was limited and most
cells did eventually die (Fig. 3, and data not shown).
Previous reports implicated autocrine and/or paracrine
FasL/CD95 signaling as a cause of the spontaneous death of
granulocytes and the chemotherapeutic drug–induced death
of certain tumor cells (9, 17, 18, 39). However, our study
demonstrated that granulocytes from CD95-deficient lpr mice
exhibit normal sensitivity to both spontaneous and drug-
induced apoptosis (Fig. 3, c and f). Consistent with our
results, other reports showed that lpr mice have normal
numbers of granulocytes and myeloid progenitors with col-
ony-forming potential (19, 20). Moreover, blocking CD95
signaling by application of neutralizing Abs to CD95, or by
elimination of caspase-8 or FADD activity, did not alter apop-
tosis of lymphocytes or mouse embryonic fibroblasts induced
by chemotherapeutic drugs or g-radiation (34, 52–54).
G-CSF promotes maturation of myeloid precursors and
can extend granulocyte life span (1, 4). It has been reported
that G-CSF can inhibit death induced by anti-CD95 Ab
treatment in human neutrophils (9). There is controversy
as to whether G-CSF can inhibit drug-induced apoptosis of
granulocytes. One report showed that G-CSF attenuates
the cytotoxic effect of etoposide on myeloid cells in vivo
(55), but another claimed that G-CSF enhanced Ara-C–
induced apoptosis of myeloid leukemia cells (56). Our results
show that G-CSF can delay spontaneous death and provide
significant protection against etoposide- or doxorubicin-
mediated killing but has no effect on FasL-induced apopto-
sis (Fig. 4, a–e). Mobilization of granulocytes to a site of in-
flammation in vivo did not alter their sensitivity to either
etoposide or FasL (Fig. 4, f and g). These observations con-
flict with reports that priming of granulocytes with LPS,
GM-CSF, or G-CSF interferes with anti-CD95 Ab–induced
apoptosis (9, 18). Although this may indicate a difference
between human peripheral blood granulocytes and murine
bone marrow–derived granulocytes, we prefer the explana-
tion that this discrepancy is due to the fact that anti-CD95
Abs do not reliably mimic the physiological ligand for
CD95 (23).
Inflammatory cytokines or LPS can influence survival of
granulocytes by increasing the expression of antiapoptotic
members of the Bcl-2 family such as A1 or Mcl-1 (5–7,
15). We observed low level expression of Bcl-2, Bcl-XL,
and Bcl-w in granulocytes, but this was not increased by
treatment with G-CSF (Fig. 5). Although no granulocytic
abnormalities have been reported in Bcl-2–, Bcl-w–, or
Bcl-XL–deficient mice (57–59), all of these proteins con-
tribute in a redundant manner to the regulation of granulo-
cyte survival since A1-deficiency enhances granulocyte
death only to a limited extent (16). It would be interesting
to investigate the impact of deficiency for both A1 plus
Bcl-2, Bcl-w, or Bcl-XL.
G-CSF might also downregulate the expression or activ-
ity of proapoptotic Bcl-2 family members. The delayed ap-
optosis of granulocytes from patients with inflammatory
diseases has been ascribed to reduced levels of Bax because
its levels in human granulocytes rose during culture in sim-
ple medium, and the rise was blocked by inflammatory cy-
tokines such as IL-3, G-CSF, or GM-CSF (60). We ob-
served that Bax was constitutively expressed in cultured
mouse granulocytes, but its level was not influenced by
G-CSF (Fig. 5). Although we detected only very low levels
of Bim by a highly sensitive immunoprecipitation/Western
blotting technique (data not shown), it must play a role in
granulocyte apoptosis because Bim-deficient mice have a
threefold excess of granulocytes  (61). This is consistent
with the finding that Bim, although expressed at very low
levels, is an essential inducer of lymphocyte apoptosis (61).
It appears that the activity of some proapoptotic Bcl-2 fam-
ily members is regulated primarily at a posttranslational
level. For example, Bim is inactivated by sequestration to
microtubules in healthy cells but is released after cytokine
withdrawal to unleash its proapoptotic function (62).
The stress-activated kinase p38 MAPK has been shown655 Villunger et al.
to activate transcription factors such as myocyte enhancer
factor 2 or activating transcription factor 2 (21), and has also
been implicated in the activation of nuclear factor (NF)-kB
signaling (63). p38 MAPK has also been reported to act as
an activator of cell death induced by g-radiation, growth
factor deprivation, or B cell receptor cross-linking (40, 64–
66). Conflicting results have been published regarding the
involvement of p38 MAPK in the regulation of granulo-
cyte apoptosis. One study reported that stress-induced but
not spontaneous apoptosis depends on p38 MAPK activity
(12), whereas another report implicated p38 MAPK activa-
tion in spontaneous granulocyte death (11). Neither study
found any evidence for activation of p38 MAPK by anti-
CD95 Ab treatment (11, 12). In contrast, we found that
multimerized FasL enhanced p38 MAPK activity in wt but
not lpr granulocytes (Fig. 6). Unexpectedly, we found that
application of specific inhibitors of p38 MAPK accelerated
spontaneous death of granulocytes in vitro (Fig. 7 a). The
cytotoxicity resulting from p38 MAPK inhibition induced
apoptotic death, since it was prevented by application of
zVADfmk or overexpression of Bcl-2 (Fig. 8, a and b).
Similarly, preincubation of granulocytes with G-CSF also
prevented the cell death induced by inhibition of p38
MAPK (Fig. 7 a). Although human granulocytes derived
from peripheral blood may respond differently to p38
MAPK inhibition than murine granulocytes derived from
bone marrow, we conclude that p38 MAPK activation is
part of a general stress response that mediates survival in
granulocytes, and that G-CSF signaling can substitute for
p38 MAPK, probably by inducing A1 or Mcl-1 expression.
Given the observation that p38 MAPK mediates NF-kB
activation in LPS-stimulated granulocytes (63), it is con-
ceivable that this might lead to the transcriptional activation
of certain antiapoptotic Bcl-2 family members that might
mediate the antiapoptotic effect of LPS. This model would
be consistent with the observation of Rel/NF-kB–medi-
ated transcriptional activation of A1 in lymphocytes (67). In
further agreement with our findings, the p38 MAPK inhib-
itor SB202190 was recently shown to enhance UV- and
anti-CD95–induced apoptosis in Jurkat and HeLa cells
(68), and p38 MAPKa2/2 embryonic stem cells were
shown to have normal sensitivity to treatment with stauro-
sporine or doxorubicin (69). Taken together, these results
make an essential role for p38 MAPK in the mediation of
apoptosis unlikely but rather indicate that it has a prosur-
vival function. p38 MAPK might therefore be a useful tar-
get in the treatment of inflammatory diseases to prevent ac-
cumulation of granulocytes.
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